__timestamp | Alpine Immune Sciences, Inc. | AstraZeneca PLC |
---|---|---|
Wednesday, January 1, 2014 | 12199547 | 5579000000 |
Thursday, January 1, 2015 | 16054000 | 5997000000 |
Friday, January 1, 2016 | 23316000 | 5890000000 |
Sunday, January 1, 2017 | 10626000 | 5757000000 |
Monday, January 1, 2018 | 28970000 | 5932000000 |
Tuesday, January 1, 2019 | 35847000 | 5958000000 |
Wednesday, January 1, 2020 | 27185000 | 5991000000 |
Friday, January 1, 2021 | 58742000 | 9736000000 |
Saturday, January 1, 2022 | 70243000 | 9762000000 |
Sunday, January 1, 2023 | 80904000 | 10935000000 |
Monday, January 1, 2024 | 13583000000 |
Data in motion
In the dynamic world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, AstraZeneca PLC and Alpine Immune Sciences, Inc. have showcased contrasting R&D investment strategies. AstraZeneca, a global giant, consistently allocated substantial resources, with R&D expenses peaking at approximately $10.9 billion in 2023, marking a 96% increase from 2014. This commitment underscores AstraZeneca's relentless pursuit of groundbreaking therapies.
Conversely, Alpine Immune Sciences, a nimble biotech firm, demonstrated a more modest yet steadily increasing R&D investment, growing by over 560% from 2014 to 2023. This growth trajectory highlights Alpine's strategic focus on innovation within its niche. The juxtaposition of these two companies offers a fascinating glimpse into how different scales of operation approach the challenge of innovation in the pharmaceutical industry.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
AstraZeneca PLC vs Alkermes plc: Strategic Focus on R&D Spending
AstraZeneca PLC vs Amneal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
AstraZeneca PLC or Soleno Therapeutics, Inc.: Who Invests More in Innovation?
Zoetis Inc. or Alpine Immune Sciences, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alpine Immune Sciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Alpine Immune Sciences, Inc.
R&D Insights: How Incyte Corporation and Alpine Immune Sciences, Inc. Allocate Funds
Research and Development Investment: Axsome Therapeutics, Inc. vs Alpine Immune Sciences, Inc.
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs CymaBay Therapeutics, Inc.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc.